The private equity business within Goldman Sachs Asset Management has acquired Norgine Europe B.V.
The deal is a milestone in Norgine’s history, following more than 110 years of ownership by the Stein family, which will continue to own a significant stake in the company. Terms of the deal were not disclosed.
Norgine is a European specialty pharmaceutical company that has strived to deliver innovative medicines to patients for more than a century. Its European experience, fully integrated infrastructure and partnership approach allow it to apply solutions to bring patients medicines that they may not otherwise be able to access. Norgine helped 24 million patients around the world in 2021 and generated €505 million ($536 million) in net product sales, representing growth of 10% over 2020. Norgine has a presence in 16 European countries as well as Australia and New Zealand and employs more than 1,500 people.
Bringing together traditional and alternative investments, Goldman Sachs Asset Management (GSAM) provides clients around the world with a dedicated partnership and focus on long-term performance. As the primary investing area within Goldman Sachs, GSAM delivers investment and advisory services for the world’s leading institutions, financial advisors and individuals, drawing from its deeply connected global network and expert insights, across every region and market — overseeing more than $2 trillion in assets under supervision worldwide as of March 31, 2022.
According to the LevinPro HC database, this was the 92nd Pharmaceuticals deal of 2022. This compares with 59 Pharmaceuticals transactions reported between January 1, 2021, and December 16, 2021.
